Contact
searchSearch
HMP Global
Login
Claire Harrison, MD
Videos
Pelabresib Plus Ruxolitinib Demonstrates Deep Clinical Responses for Patients With Myelofibrosis: MANIFEST-2 Trial
09/26/2025
Claire Harrison, MD
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Claire Harrison, MD, shares...
09/26/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Ziftomenib Plus Standard Induction Therapy Demonstrates Meaningful Clinical Activity for Patients With AML: KOMET-007
08/25/2025
Amer Zeidan, MBBS
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer...
08/25/2025
Oncology
Stefano Luminari, MD
Videos
Odronextamab Demonstrates Long-Term High Response Rates for Heavily Pretreated R/R Follicular Lymphoma: ELM-2
07/25/2025
Stefano Luminari, MD
At the EHA 2025 Congress, Stefano Luminari, MD shared results from the ELM-2 trial which evaluated the efficacy of odronextamab therapy for patients with relapsed/refractory follicular lymphoma with a follow-up of more than 2 years.
At the EHA 2025 Congress, Stefano Luminari, MD shared results from the ELM-2 trial which evaluated the efficacy of odronextamab therapy for patients with relapsed/refractory follicular lymphoma with a follow-up of more than 2 years.
At the EHA 2025 Congress,...
07/25/2025
Oncology
Raul Cordoba, MD
Conference Coverage
Epcoritamab Plus R-ICE Shows Deep Responses and Manageable Safety for Patients With DLBCL Eligible for ASCT: EPCORE NHL-2 Trial
07/10/2025
Raul Cordoba
At the EHA 2025 Congress, Raul Cordoba shared results from the EPCORE NHL-2 trial which evaluated the efficacy of epcoritamab combined with R-ICE therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
At the EHA 2025 Congress, Raul Cordoba shared results from the EPCORE NHL-2 trial which evaluated the efficacy of epcoritamab combined with R-ICE therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
At the EHA 2025 Congress, Raul...
07/10/2025
Oncology
Krish Patel, MD
Conference Coverage
Dual-Target CAR T-Cell Therapy Demonstrates Promising Response Rates for R/R LBCL
06/23/2025
Krish Patel, MD
At the EHA 2025 Congress, Krish Patel, MD shares results from a clinical trial assessing the safety and efficacy of JNJ-90014496, a novel CD19-CD20 CAR T-cell therapy for the treatment of large b-cell lymphoma.
At the EHA 2025 Congress, Krish Patel, MD shares results from a clinical trial assessing the safety and efficacy of JNJ-90014496, a novel CD19-CD20 CAR T-cell therapy for the treatment of large b-cell lymphoma.
At the EHA 2025 Congress, Krish...
06/23/2025
Oncology
Vincent Ribrag, MD
Videos
BTK Inhibitors in Combination With Other Therapies as First-Line Treatment for Patients With Mantle Cell Lymphoma
06/27/2023
Vincent Ribrag, MD
At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.
At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.
At the 2023 EHA Congress,...
06/27/2023
Oncology
News
PI3Kd Inhibitor YY-20394 Well Tolerated in Patients With R/R FL
10/19/2021
Phase 2 studying findings presented at the 2021 EHA Congress demonstrate the clinical efficacy of the PI3Kd inhibitor YY-20394 for the treatment of patients with R/R FL.
Phase 2 studying findings presented at the 2021 EHA Congress demonstrate the clinical efficacy of the PI3Kd inhibitor YY-20394 for the treatment of patients with R/R FL.
Phase 2 studying findings...
10/19/2021
Oncology
Dr Lydia Scarfò
Videos
MRD-Driven Therapy With Ibrutinib Plus Venetoclax for R/R CLL
08/12/2021
Lydia Scarfò, MD, discusses an MRD-driven treatment strategy with ibrutinib and venetoclax for R/R CLL. These data were presented at the 2021 EHA Virtual Congress.
Lydia Scarfò, MD, discusses an MRD-driven treatment strategy with ibrutinib and venetoclax for R/R CLL. These data were presented at the 2021 EHA Virtual Congress.
Lydia Scarfò, MD, discusses an...
08/12/2021
Oncology
Dr
Videos
Jeff Kutok, MD, PhD, on Targeting SETD2 in the Treatment of MM
06/28/2021
Dr Kutok discusses preclinical data which were presented at the EHA2021 Virtual Congress that support the targeting of SEDT2 in patients with MM.
Dr Kutok discusses preclinical data which were presented at the EHA2021 Virtual Congress that support the targeting of SEDT2 in patients with MM.
Dr Kutok discusses preclinical...
06/28/2021
Oncology
Videos
Sagar Lonial, MD, Discusses the TOURMALINE-MM4 Study
08/01/2020
Dr Lonial discusses a study on ixazomib as post-induction maintenance therapy for transplant-ineligible, newly-diagnosed MM.
Dr Lonial discusses a study on ixazomib as post-induction maintenance therapy for transplant-ineligible, newly-diagnosed MM.
Dr Lonial discusses a study on...
08/01/2020
Oncology
News
BTK Inhibitor Therapy Effective for Patients With High-Risk, Progressive CLL
07/17/2020
BTK inhibitor therapy is an effective option for patients with CLL resistant to venetoclax, according to data presented at the virtual 2020 EHA Annual Congress.
BTK inhibitor therapy is an effective option for patients with CLL resistant to venetoclax, according to data presented at the virtual 2020 EHA Annual Congress.
BTK inhibitor therapy is an...
07/17/2020
Oncology
Videos
Venetoclax Added to Azacitidine Improves Responses, OS in Older Patients With AML
07/15/2020
Courtney DiNardo, MD, discusses the results from the VIALE-A study, which evaluated azacitidine with or without venetoclax in older patients with newly diagnosed AML.
Courtney DiNardo, MD, discusses the results from the VIALE-A study, which evaluated azacitidine with or without venetoclax in older patients with newly diagnosed AML.
Courtney DiNardo, MD, discusses...
07/15/2020
Oncology
Videos
Addition of Parsaclisib to Ruxolitinib Therapy Shows Promise for Patients With Myelofibrosis
07/02/2020
Abdulraheem Yacoub, MD, discusses the results from a phase 2 study, which evaluated optimal dosing and efficacy of the addition of parsaclisib in patients with myelofibrosis with suboptimal response on ruxolitinib.
Abdulraheem Yacoub, MD, discusses the results from a phase 2 study, which evaluated optimal dosing and efficacy of the addition of parsaclisib in patients with myelofibrosis with suboptimal response on ruxolitinib.
Abdulraheem Yacoub, MD,...
07/02/2020
Oncology
Videos
Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL
06/29/2020
Arnon P. Kater, MD, PhD, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax in patients with relapsed/refractory CLL.
Arnon P. Kater, MD, PhD, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax in patients with relapsed/refractory CLL.
Arnon P. Kater, MD, PhD,...
06/29/2020
Oncology
Videos
Roberto Mina, MD, Discusses Preliminary Results from the UNITO-EMN10 Study
06/26/2020
Roberto Mina, MD, discusses results from the randomized, phase 2 UNITO-EMN10 study evaluating ixazomib combinations and maintenance in transplant-ineligible patients with newly diagnosed MM.
Roberto Mina, MD, discusses results from the randomized, phase 2 UNITO-EMN10 study evaluating ixazomib combinations and maintenance in transplant-ineligible patients with newly diagnosed MM.
Roberto Mina, MD, discusses...
06/26/2020
Oncology
Conference Insider
Asciminib Well-Tolerated, Active in Heavily Pretreated Ph+ CML
06/23/2020
Asciminib is well-tolerated and shows promising clinical activity in patients with Ph+ CML with baseline BCR-ABL1 levels less than 1%.
Asciminib is well-tolerated and shows promising clinical activity in patients with Ph+ CML with baseline BCR-ABL1 levels less than 1%.
Asciminib is well-tolerated and...
06/23/2020
Oncology
Videos
Ibrutinib Plus Venetoclax Yields High Rates of Undetectable MRD in CLL
06/22/2020
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses the results of the MRD cohort of the CAPTIVATE trial, a multicenter phase 2 trial evaluating ibrutinib plus venetoclax in CLL and SLL.
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses the results of the MRD cohort of the CAPTIVATE trial, a multicenter phase 2 trial evaluating ibrutinib plus venetoclax in CLL and SLL.
Constantine Tam, MBBS (Hons),...
06/22/2020
Oncology
Conference Insider
Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM
06/22/2020
Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.
Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.
Ixazomib in combination with...
06/22/2020
Oncology
Conference Insider
Dasatinib Added to Induction Therapy Improves Outcomes in Ph+ ALL
06/19/2020
Dasatinib added to 2-step induction therapy improves pre-transplant treatment for patients with Philadelphia chromosome-positive ALL.
Dasatinib added to 2-step induction therapy improves pre-transplant treatment for patients with Philadelphia chromosome-positive ALL.
Dasatinib added to 2-step...
06/19/2020
Oncology
Videos
Triplet Combination Appears Well-Tolerated, Safe for DLBCL
06/18/2020
Charles Herbaux, MD, MSc, discusses results from the phase 2 GATA study, which evaluated the efficacy and safety of obinutuzumab plus atezolizumab and venetoclax for relapsed/refractory DLBCL.
Charles Herbaux, MD, MSc, discusses results from the phase 2 GATA study, which evaluated the efficacy and safety of obinutuzumab plus atezolizumab and venetoclax for relapsed/refractory DLBCL.
Charles Herbaux, MD, MSc,...
06/18/2020
Oncology
Videos
Subcutaneous Daratumumab Plus CyBorD Improves Outcomes in AL Amyloidosis
06/18/2020
Raymond Comenzo, MD, discusses results from the ANDROMEDA trial, which showed superiority with the addition of daratumumab to CyBorD over CyBorD alone for patients with AL amyloidosis.
Raymond Comenzo, MD, discusses results from the ANDROMEDA trial, which showed superiority with the addition of daratumumab to CyBorD over CyBorD alone for patients with AL amyloidosis.
Raymond Comenzo, MD, discusses...
06/18/2020
Oncology
Conference Insider
PET-CT Status After First Line Immunochemotherapy Prognostic for Survival in FL
06/17/2020
Achieving a PET-CT complete metabolic response after first line immunochemotherapy is strongly associated with improved survival outcomes in FL.
Achieving a PET-CT complete metabolic response after first line immunochemotherapy is strongly associated with improved survival outcomes in FL.
Achieving a PET-CT complete...
06/17/2020
Oncology
Videos
Glofitamab Demonstrates Strong Efficacy, Manageable Safety in Relapsed/Refractory NHL
06/17/2020
Michael Dickinson, MBBS (Hons), D.Med Sci, FRACP, FRCPA, discusses the results of a phase 1 dose escalation study of glofitamab in relapsed/refractory NHL.
Michael Dickinson, MBBS (Hons), D.Med Sci, FRACP, FRCPA, discusses the results of a phase 1 dose escalation study of glofitamab in relapsed/refractory NHL.
Michael Dickinson, MBBS (Hons),...
06/17/2020
Oncology
Videos
Acalabrutinib Demonstrates Favorable Safety and Efficacy in Relapsed/Refractory CLL
06/17/2020
Paolo Ghia, MD, PhD, discusses the results from the ASCEND study, which compared acalabrutinib monotherapy to physician’s choice of therapy in patients with relapsed or refractory CLL.
Paolo Ghia, MD, PhD, discusses the results from the ASCEND study, which compared acalabrutinib monotherapy to physician’s choice of therapy in patients with relapsed or refractory CLL.
Paolo Ghia, MD, PhD, discusses...
06/17/2020
Oncology

The EHA Annual Congress is a flagship meeting held in a major European city every June—a significant meeting place for hematologists from every area of specialization. The annual congresses encompass the entire spectrum of hematological studies, where over 11,000 participants can learn about the latest findings and innovations in hematologic diseases.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use